Loading...
Cancer Therapeutics Training (CT2) Talks | Charles Theuer, MD, PhD
Details
Events
General
University of California, San Diego
La Jolla, California
Listed a day ago
Date Posted January 4, 2026 12:21 PM
Event Details
Format
hybrid
Location and Room
Comer Commons, Moores Cancer Center
Address
La Jolla, California
Description
Subcutaneous Delivery of Antibody Drug Conjugates
Dr. Theuer has been Chief Medical Officer at Halozyme since October 2024 where he is responsible for providing leadership and guidance to Halozyme and its partners/collaborators insubcutaneous drug development with ENHANZE® technology and auto-injectors.
Before joining Halozyme, Dr. Theuer served as Chief Executive Officer, Chief Medical Officer,and Director of TRACON Pharmaceuticals, where he worked to transform outcomes for cancer patients and optimize clinical development operations. His career includes senior medical leadership positions at TargeGen Inc. where, as Chief Medical Officer, he directed the development of Inrebic®, Pfizer where he led the clinical development of Sutent® in renal cell carcinoma and IDEC Pharmaceuticals where he oversaw clinical trials of Rituxa...
CT2
Seller information
Share this listing
Help others discover this itemCancer Therapeutics Training (CT2) Talks | Charles Theuer, MD, PhD
Details
Events
General
University of California, San Diego
La Jolla, California
Listed a day ago
Date Posted January 4, 2026 12:21 PM
Event Details
Format
hybrid
Location and Room
Comer Commons, Moores Cancer Center
Address
La Jolla, California
Description
Subcutaneous Delivery of Antibody Drug Conjugates
Dr. Theuer has been Chief Medical Officer at Halozyme since October 2024 where he is responsible for providing leadership and guidance to Halozyme and its partners/collaborators insubcutaneous drug development with ENHANZE® technology and auto-injectors.
Before joining Halozyme, Dr. Theuer served as Chief Executive Officer, Chief Medical Officer,and Director of TRACON Pharmaceuticals, where he worked to transform outcomes for cancer patients and optimize clinical development operations. His career includes senior medical leadership positions at TargeGen Inc. where, as Chief Medical Officer, he directed the development of Inrebic®, Pfizer where he led the clinical development of Sutent® in renal cell carcinoma and IDEC Pharmaceuticals where he oversaw clinical trials of Rituxa...
CT2